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Reductions in uteroplacental ﬂow initiate a cascade of molecular eﬀects leading to hypoxia, thrombosis, inﬂammation, and
endothelialcelldysfunctionresultinginuntowardpregnancyoutcomes.Inthisreview,wedetailtheseeﬀectsandtheirrelationship
to preeclampsia (PE) and intrauterine growth restriction (IUGR).
1.Introduction
PE is universally deﬁned as hypertension and signiﬁcant pro-
teinuria developed at or after 20 weeks of pregnancy in an
otherwise normotensive woman [1–3]. PE is a multisystem
disorder which complicates 3–14% of all pregnancies and
about 5–8% of pregnancies in the United States [1]. The
disease is mild in 75% of cases in the United States, and
severe in 25% of cases [4]. Ten percent of PE occurs in
pregnancies less than 34 weeks of gestation. The incidence
of PE has risen in the USA in the last decades [5]. This
ﬁnding might be related to an increased prevalence of
predisposing disorders, such as maternal age, chronic
hypertension, diabetes, prepregnancy obesity, and multiple
births [5–7]. Overall, 10%–15% of direct maternal deaths
are associated with PE in low- and middle-income countries
and the proportion is similar in high-income countries
[8, 9]. Furthermore, severe PE is a major cause of maternal
morbidity (i.e., stroke and liver rupture) and negative long-
term outcomes (i.e., cardiovascular disease and diabetes mel
litus) as well as adverse perinatal eﬀects, such as prematurity
and intrauterine growth restriction [5, 10].
While much research has been devoted toward this topic,
the cause of PE still remains elusive. Two diﬀerent theories
have emerged: (1) vascular-ischemic origin of PE and (2)
impaired immune response [11]. A current hypothesis uni-
ﬁes these concepts where an altered immune response leads
to disturbed placental function early in pregnancy with
consequent syncytiotrophoblast ischemia and shedding of
products that extensively damage endothelial integrity. This
in turn results in an exponential production of multiple
factors such as cytokines and growth factors leading to the
clinicalmanifestationsofPE[11].Howtheimmuneresponse
can activate the cascade process is still unknown but it is pro-
posed to act in synergy with additional exacerbating factors
such as predisposing maternal and ambient factors [12].
2. Angiogenic Factorsand PE
Angiogenic factors and their receptors are important reg-
ulators of placental vascular development [13]. The most
widely studied serum markers for PE, to date, are vascular
endothelial growth factor (VEGF) and placental growth
factor (PlGF). Antagonists include soluble fms-like tyrosine
kinase 1 (sFlt-1, also known as sVEGFR1), and soluble
endoglin (sEng) [13].
sFlt-1 is a truncated splice variant of the membrane-
bound Flt1; it consists of the extracellular binding domain
without the intracellular signaling domain. Several studies
demonstrated the association of increased sFlt-1 with PE
[14, 15].
EvidencefortheinvolvementofsFlt1intheoccurrenceof
PEwasinitiallyprovidedbyananimalmodelinwhichgravid
rats were infected with a recombinant adenovirus encoding
sFlt1 and compared to animals infected with the empty con-
trol adenovirus. The animals infected with sFlt1 developed2 Journal of Pregnancy
a syndrome highly reminiscent of human PE: hypertension
and proteinuria due to a glomerular endotheliosis [14, 16].
Similarly, sEng is a truncated form of receptor for two
subtypes of transforming growth factor beta (TGFβ) specif-
ically, TGFβ1a n dT G F β2 which are highly expressed by vas-
cular endothelial cells and syncytiotrophoblasts. Like sFlt1,
solubleendoglin(sEng)isanantiangiogenicfactorcapableof
inhibiting capillary tube formation in vitro [17]. Soluble Eng
also increases vascular permeability; overexpression of both
sFlt1 and sEng in rodents results in capillary permeability in
the lungs, kidneys, and liver [18]. Overexpression of both
sEng and sFlt1 in pregnant rats develops nephrotic-range
proteinuria, severe hypertension, biochemical evidence of
HELLP (“H” for hemolysis, “EL” for elevated liver enzymes,
and “LP” for low platelet count), and intrauterine growth
restriction of the pups [19, 20].
PlGF concentration during pregnancy increases during
the ﬁrst 30 weeks of gestation, and then decreases [13].
Longitudinal studies have shown that a relatively low PlGF
concentration(whichcouldbeexplainedbyahighsFlt1con-
c e n t r a t i o n )i sa l s oac h a r a c t e r i s t i cf e a t u r eo fP E .D e c r e a s e d
levels of urinary PlGF and PIGF:sFlt-1 ratio during mid-
gestation have been proposed as a predictive model for
developmentofclinicalPE,andquantiﬁcationofsFlt-1levels
has correlated directly with severity of disease and inversely
with time to onset of proteinuria and hypertension [21].
The exact molecular basis for placental dysregulation
of these factors remains unknown but hypoxia is likely an
important regulator [22]. Other factors such as alterations
intherenin-angiotensin-aldosteroneaxis,immunemaladap-
tion, excessive shedding of trophoblast debris, oxidative
stress, and genetic factors likely contribute to the pathogen-
esis of the abnormal placentation [22]. To date the most
successful treatment for PE is delivery.
3.Preeclapmpsiaand
Cathecol-O-methyltrasferase
Cathecol-O-methyltrasferase (COMT) catalyzes the O-
methylation of various circulating hormones such as cate-
cholamines and catecholestrogens [23, 24]. In the placenta,
COMT metabolizes certain forms of circulating estradiols
to the molecule 2-methyl estradiol (2-ME). This estradiol
metabolitehasseveraleﬀects,onebeingthedestabilizationof
hypoxia-inducible factor- (HIF-) 1α3 in the cytoplasm. HIFs
areheterodimericproteinsthatmediatetheeﬀectsofhypoxia
on gene expression by upregulating transcription of target
genes including sFlt1 [25]. This role of COMT in main-
taining oxygen balance suggests that COMT might some-
how be involved in the pathogenesis of PE.
To better elucidate the role of COMT in PE, a genetic
COMT knockout (COMT−/−)m o u s em o d e lw a sr e c e n t l y
developed. Interestingly, pregnant COMT−/− mice devel-
oped a PE-like phenotype characterized by proteinuria, in-
creased blood pressure, and histopathological changes in the
placenta and kidney. This phenotype was accompanied by
lower plasma concentrations of 2-ME and higher placental
protein levels of HIF-1a [26]. Restoration of 2-ME in
COMT−/− mice decreased HIF-1a and ameliorated the
preeclamptic phenotype [26]. Together, these results suggest
thatCOMTand2-MEdeﬁciencymightplayasigniﬁcantrole
in the development of PE.
The exact mechanism by which 2-ME prevents PE re-
mains unknown. Although 2-ME was found to suppress
HIF-1a and sFlt1, recent experiments suggest that there
might be several other mechanisms through which 2-ME
promotes vascular health [27].
Lastly, recent evidence suggests that 2-ME is necessary
for cytotrophoblast invasion of the maternal decidua and
therefore contributes to the prevention of PE by promoting
normal placental vascular formation [28]. Further studies on
this topic will be required to ascertain a more exact mech-
anism of action.
4. PE and Complement Factors
The complement system, composed of over 30 proteins that
act in concert to protect the host against invading organisms,
initiates inﬂammation and tissue injury [29] and normally
has a protective role toward oﬀ-infection. Complement ac-
tivation promotes chemotaxis of inﬂammatory cells and
generates proteolytic fragments that enhance phagocytosis
by neutrophils and monocytes. There is scant information
about complement activation in normal and abnormal
human pregnancy [30]. During normal gestation, serum
levels of C3, C4, and total hemolytic complement (CH50)
gradually increase 10%–50% [31]. Studies have shown sig-
niﬁcantelevationsinlevelsofBb,C3a,C4d,andsolubleC5b-
9 in preeclampsia, indicating excess activation of both the
classical and alternative complement pathway [32]. Lynch
et al. conducted a large prospective study in human preg-
nancy to investigate whether elevated levels of complement
activation fragment Bb (reﬂecting alternative complement
pathway activation) at a single point in early pregnancy (less
than 20 weeks gestation) were predictive of preeclampsia
later in pregnancy. Adjusted for other risk factors, women
with higher levels of Bb in early pregnancy were almost four
times more likely to develop preeclampsia later in pregnancy
compared with women with levels less than the top decile in
early pregnancy [33]. Products of complement pathway have
beenfoundindeciduas,chorionicvilli,andassubendothelial
deposits in vessel walls in normal and preeclampsia [34,
35]. A recent study reported that the presence in C5b-9
MAC on trophoblasts was associated with ﬁbrin deposits
at sites of villous injury in vivo in normal placentas, but
especially in placentas from pregnancies complicated by
IUGR or preeclampsia [36]. It has been demonstrated that
in normal pregnancies, complement regulatory proteins
that are highly expressed on trophoblast membranes pre-
vent excessive complement activation (membrane cofactor
protein [MCP (CD46)], decay accelerating factor [DAF
(CD55)], and CD59)) as well as circulating complement reg-
ulatory proteins (complement factor H [CFH], C4b binding
protein, and complement factor I [CFI]) [37, 38]. Defective
regulation of the complement system allows for the excessive
complement activation that leads to placental damage,Journal of Pregnancy 3
abnormal placental development, generalized endothelial
activation, and the release of antiangiogenic factors toxic
to the fenestrated endothelium of glomeruli, the choroid
plexus, and liver sinusoids—a sequence of events that culmi-
nates in clinical preeclampsia [39]. The link between com-
plement activation and pathogenic events in preeclampsia
identiﬁes potential biomarkers to predict patients at risk for
preeclampsia and new targets to prevent its complications.
5. PE andCoagulation Factors
As implied in the preceding section, insuﬃcient and/or inad-
equate trophoblastic invasion of the maternal spiral arteries
leads to reduced uteroplacental blood ﬂow causing focal
decidual hypoxia, and thus VEGF [40–42]. This in turn
results in activation of the decidual endothelial cells and
the aberrant expression of tissue factor (TF) [40, 43]. In
addition, under pathological conditions, other cells, such
as macrophages present in the maternal fetal interface, can
also generate TF. TF generates thrombin that further induces
endothelial cell TF expression and inﬂammatory cytokines
[40]. Both VEGF and TF induce aberrant angiogenesis and
poor vessel maintenance reﬂected by endothelial cell fenes-
trationsandinductionofaprothromboticsurfaceandutero-
placental vascular insuﬃciency [44].
Under physiological conditions, TF is not expressed by
endothelial cells. By contrast, endothelial TF expression is
observed in pathologic conditions such as sepsis, atheroscle-
rosis, and rapid but malformed vessel growth associated with
malignancies and allograft rejection [45–47]. Indeed, ex-
pression of TF by the endothelium is a pathological conse-
quence of cross-talk between coagulation and inﬂammatory
cytokines [45]. Expression of TF transforms endothelial
cell membrane from an anticoagulant to a procoagulant
surface and promotes intravascular thrombosis [48, 49].
Interestingly, the uteroplacental vasculature of pregnancies
complicated by PE and IUGR display vascular features sim-
ilar to those seen in allograft rejection [50]. A recent study by
Di Paolo et al. demonstrated high expression of TF mRNA in
the vascular endothelium of vessels in the decidua basalis of
pregnancies complicated by PE and IUGR but not in normal
pregnancies [51].
Tissue factor, the critical initiator of the coagulation cas-
cade, is induced during pregnancy in the maternal decidua
[52, 53] and is plentiful in the placenta and amniotic ﬂuid
[54–57]. It has been well documented that patients with
diseases leading to aberrantly increased circulating TF ex-
pression have a much higher rate of vascular thromboembo-
lism (VTE) [58–61]. Speciﬁcally, patients are at risk for car-
diovascular diseases, sepsis, hematologic, and coagulation
disorders such as disseminated intravascular coagulation
[62–67]. In these diseases, as well as in cancer and diabetes,
plasma TF is related to increased blood thrombogenicity
[67]. Interestingly, plasma levels of thrombomodulin activ-
ity, tissue factor activity, and procoagulant phospholipids
were signiﬁcantly elevated in women with PE versus normal
pregnant and nonpregnant women [68]. Moreover, the cir-
culating TF has been identiﬁed on circulating microparticles
(MPs). These MPs are small vesicles released from injured
or activated cells, primarily leukocytes and endothelial cells
[58, 69]. TF-bearing MPs in pregnancy also arise from syn-
cytiotrophoblasts [70] and excess syncytiotrophoblast mi-
croparticles have been found in the circulation of women
with PE [71]. Unfortunately, VTE is one of the leading caus-
esofmorbidityandmortalityduringpregnancy[72].Ahigh-
er prevalence of risk factors for VTE has been found in
women with PE and fetal loss [73].The principal factors that
result in venous thrombosis consist of the classic triad of Vir-
chow: venous stasis, vascular damage, and hypercoagulabili-
ty, all of which occur during normal pregnancies [74]. A
shift of the hemostatic balance in the direction of hypercoag-
ulability during pregnancy is believed to be evolutionarily
advantageous in reducing hemorrhage, however, this could
also contribute to the increased risk of venous thromboem-
bolic processes [75]. Studies from our laboratory have
demonstrated that TF is normally expressed by decidual
cells [76]. Indeed, immunohistochemical staining for TF has
been observed in the decidualized endometrial stromal cells,
but not in endothelial cells [77–79]. In contrast, we noted
that basal plate uteroplacental vessel segments from cases
of low birth weight with villous evidence of maternal uter-
oplacentalmalperfusionhadincreasedpercentofstrongpos-
itive endothelial immunostaining for TF [40].
6.ThrombinActivationofEndometrial
EndothelialCells
Vascular injury initiates clotting when plasma-derived fac-
tor VII binds to the extracellular domain of perivascular
cell membrane-bound TF. The resulting TF/VIIa complex
promotes hemostasis via a series of changes initiated by
the extracellular cleavage of prothrombin to thrombin [76].
The aberrant expression of TF in vessels from deciduas
with activated endothelium led us to study this phe-
nomenon in further detail. We proposed that aberrantly
expressed TF in decidual vessels would in turn result in
thrombin production and further endothelial activation. In
vitro experiments were carried out with cultured human
endometrial endothelial cells (HEECs) [40]. Treatment with
2.5U of thrombin demonstrated the induction of TF protein
and mRNA expression [40]. Moreover, thrombin-induced
inﬂammatory cytokine expression in HEECs. Speciﬁ-
cally thrombin signiﬁcantly upregulated mRNA expression
for regulated upon activation, normal T-cell expressed,
and secreted (RANTES) chemokine, growth-related onco-
gene (Gro)-β,G r o - γ, granulocyte chemotactic protein
(GCP)-2, granulocyte-macrophage colony stimulating fac-
tor (GM-CSF), monocyte chemotactic protein-1 (MCP-1),
interleukin-8 (IL-8), and macrophage inﬂammatory protein
3α(MIP3α)[40].Thisincreaseinproinﬂammatorychemok-
ines are expected to result in endothelial dysfunction or in-
appropriate endothelial cell activation which are the most
common clinical manifestations in PE, including enhanced
endothelial-cell permeability and platelet aggregation [80].
Moreover, the overexpression of these chemokines is consis-
tent with observations made in our laboratory [81, 82]a s4 Journal of Pregnancy
well as others [83, 84] indicating that the preeclamptic de-
cidua contains an excess of macrophages [82].
7. Summary
To date, no accurate test exists for predicting PE. In recent
years, it has become accepted that early-onset and late-onset
PEs are associated with diﬀerent biochemical, histological,
and clinical features [85]. Moreover, markers such as sFLT,
sEng, products of fetal and placental origin, markers of renal
or endothelial damage, or markers of oxidative stress are sec-
ondary to the pathophysiological changes that precede the
clinical onset of PE [85]. Nonetheless, a combination of
markers may increase the detection accuracy earlier in the
pregnancy and hopefully allow for more eﬀective prophylac-
tic strategies.
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